Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 3/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234791 | 0.92 | PPARG (0.33) | KLK5CTSLKMT2A | |
| SCHEMBL2383561 | 0.91 | GABRA1 (0.33) | KLK5CTSLNR1I3CTSKKMT2A | |
| SCHEMBL2237782 | 0.91 | SCN9A (0.35) | KLK5CTSLNR1I3CTSK | |
| SCHEMBL2236735 | 0.90 | NR1I3 (0.37) | KLK5CTSLNR1I3CTSK | |
| SCHEMBL2235865 | 0.89 | NR1I3 (0.31) | NR1I3 | |
| SCHEMBL2237182 | 0.80 | MEN1 (0.41) | CTSKKMT2A | |
| SCHEMBL2238062 | 0.80 | MEN1 (0.41) | CTSKKMT2A | |
| SCHEMBL2233412 | 0.78 | SCN9A (0.39) | KLK5CTSLNR1I3CTSKKMT2A | |
| SCHEMBL2236004 | 0.74 | CPB2 (0.44) | — | |
| SCHEMBL12255867 | 0.74 | CPB2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | KLK5 2677/4885CTSL 998/4885PTPN1 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.